First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshu Liu, Michael Schenker, Patricio Yañez, Mustapha Tehfé, Rubén Dario Kowalyszyn, Michalis V. Karamouzis, Ricardo Brugés, Thomas Zander, Roberto Pazo-Cid, Erika Hitre, Kynan Feeney, James M. Cleary, Valerie Poulart, Dana Cullen, Ming Lei, Hong Xiao, Kaoru Kondo, Mingshun Li, Jaffer A. Ajani
The Lancet, 2021
Abstract
An abstract is not available for this record. Please visit the publisher website for more details.
- Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma 2022
- 1519P Fruquintinib plus sintilimab in patients (pts) with either treatment-naïve or previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results from a multicenter, single-arm phase II study 2023
- FDA approves Lonsurf for recurrent, metastatic gastric and gastroesophageal junction adenocarcinoma 2019
- Supplementary Figure 1 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study 2023
- FS-1502 in patients with HER2 high expression, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: An open-label, multicenter, phase II study. 2024
- Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie 2008
- <i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates 2014
- Clinicopathologic factors associated with HER2‐positive gastric cancer and its impact on survival outcomes—A systematic review 2011
- HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance 2013
- Impact of HER-2 Overexpression/Amplification on the Prognosis of Gastric Cancer Patients Undergoing Resection: A Single-Center Study of 1,036 Patients 2011